Connect with us


The new CBD drug that could help tackle COVID anxiety



A new CBD prescription drug is being developed to help combat the mental health crisis expected in the wake of the coronavirus pandemic.

Canandian-owend EmpowerPharm Inc is currently developing a first-of-its-kind prescription drug containing synthetic CBD as the Active Pharmaceutical Ingredient (API) manufactured as tablets to treat anxiety.

Pending the results of the clinical research, it is thought Empower CBDTM may help the hundreds-of-thousands of Canadians who suffer from anxiety, an issue that continues to skyrocket in the wake of the COVID-19 outbreak.

EmpowerPharm has identified a growing need for innovative therapies to treat anxiety and it is hoped the drug could be used as an alternative treatment to avoid the potentially addictive prescription products currently prescribed.

A CAMH report from mid-July reported that 25 percent of Canadians aged 18-39 and 19 percent aged 40-59 continue to experience moderate to severe anxiety.

Meanwhile, a Deloitte study released in August estimates Canadians will face a potentially explosive increase of mental illness for up to 10 years after the pandemic is over.

The synthetic CBD (API) used in Empower CBDTM tablets will be 99 percent pure with zero THC, and will be approved by national regulatory authorities including Health Canada and the FDA based on robust clinical evidence.

Once clinical research has been completed and proven to be effective, the prescription medicine will be sold exclusively through pharmacies or dispensed in hospitals by qualified health professionals.

EmpowerPharm is led by three prominent leaders in Canada’s pharmaceutical industry.

They plan to pursue both private and public coverage to allow for wide patient accessibility


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.